Want to take quizzes and track your credits?
Can patients at high risk for anaphylactic reactions receive the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine?
In this cohort study of 8102 individuals with an allergy history, an algorithm was used to define 429 (5%) as “highly allergic”; this group was referred to receive immunization under medical supervision. A total of 98% of the highly allergic individuals had no allergic reaction, 6 (1%) had mild allergic responses, and 3 (0.7%) had anaphylactic reactions.
This study’s findings suggest that a simple algorithm enables immunization of most patients with a history of allergy, while only patients defined as highly allergic should receive vaccination under medical supervision.
Allergic reactions among some individuals who received the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine discourage patients with allergic conditions from receiving this vaccine and physicians from recommending the vaccine.
To describe the assessment and immunization of highly allergic individuals with the BNT162b2 vaccine.
Design, Setting, and Participants
In a prospective cohort study from December 27, 2020, to February 22, 2021, 8102 patients with allergies who applied to the COVID 19 vaccine referral center at the Sheba Medical Center underwent risk assessment using an algorithm that included a detailed questionnaire. High-risk patients (n = 429) were considered “highly allergic” and were immunized under medical supervision.
Pfizer-BioNTech (BNT162b2) COVID-19 vaccine.
Main Outcomes and Measures
Allergic and anaphylactic reactions after the first and second doses of BNT162b2 vaccine among highly allergic patients.
Of the 429 individuals who applied to the COVID-19 referral center and were defined as highly allergic, 304 (70.9%) were women and the mean (SD) age was 52 (16) years. This highly allergic group was referred to receive immunization under medical supervision. After the first dose of the BNT162b2 vaccine, 420 patients (97.9%) had no immediate allergic event, 6 (1.4%) developed minor allergic responses, and 3 (0.7%) had anaphylactic reactions. During the study period, 218 highly allergic patients (50.8%) received the second BNT162b2 vaccine dose, of which 214 (98.2%) had no allergic reactions and 4 patients (1.8%) had minor allergic reactions. Other immediate and late reactions were comparable with those seen in the general population, except for delayed itch and skin eruption, which were more common among allergic patients.
Conclusions and Relevance
The rate of allergic reactions to BNT162b2 vaccine, is higher among patients with allergies, particularly among a subgroup with a history of high-risk allergies. This study suggests that most patients with a history of allergic diseases and, particularly, highly allergic patients can be safely immunized by using an algorithm that can be implemented in different medical facilities and includes a referral center, a risk assessment questionnaire, and a setting for immunization under medical supervision of highly allergic patients. Further studies are required to define more specific risk factors for allergic reactions to the BNT162b2 vaccine.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: June 16, 2021.
Published: August 31, 2021. doi:10.1001/jamanetworkopen.2021.22255
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Shavit R et al. JAMA Network Open.
Corresponding Author: Nancy Agmon-Levin, MD, Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer Hospital, Ramat-Gan 52621, Israel (firstname.lastname@example.org).
Author Contributions: Dr Agmon-Levin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Shavit, Offengenden, Machnes Maayan, Deutch, Elbaz, Rahav, Levy, Belkin, Regev-Yochay, Afek, Agmon-Levin.
Acquisition, analysis, or interpretation of data: Shavit, Maoz-Segal, Iancovici-Kidon, Offengenden, Haj Yahia, Machnes Maayan, Lifshitz-Tunitsky, Niznik, Frizinsky, Genaim, Rahav, Belkin, Regev-Yochay, Agmon-Levin.
Drafting of the manuscript: Shavit, Maoz-Segal, Offengenden, Haj Yahia, Machnes Maayan, Niznik, Frizinsky, Genaim, Rahav, Levy, Agmon-Levin.
Critical revision of the manuscript for important intellectual content: Shavit, Iancovici-Kidon, Offengenden, Lifshitz-Tunitsky, Frizinsky, Deutch, Elbaz, Rahav, Belkin, Regev-Yochay, Afek, Agmon-Levin.
Statistical analysis: Shavit, Maoz-Segal, Iancovici-Kidon, Haj Yahia, Niznik, Agmon-Levin.
Obtained funding: Agmon-Levin.
Administrative, technical, or material support: Shavit, Maoz-Segal, Offengenden, Haj Yahia, Machnes Maayan, Lifshitz-Tunitsky, Deutch, Elbaz, Belkin, Agmon-Levin.
Supervision: Frizinsky, Genaim, Rahav, Levy, Belkin, Afek, Agmon-Levin.
Conflict of Interest Disclosures: Dr Regev-Yochay reported receiving personal fees from Teva and grants from Pfizer outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by the Sheba Fund for Health Services and Research (Registered Association).
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the infectious diseases and infection prevention and control unit team for operating the COVID-19 referral center, and specifically Vered Roa, BA, Infection Prevention & and Control Unit, Sheba Medical Center; she was not compensated for her contribution.
You currently have no searches saved.
You currently have no courses saved.